We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

EPT 100: Geranium Oil for the Relief of Neuropathic Pain (Geranium Oil)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01007747
Recruitment Status : Completed
First Posted : November 4, 2009
Last Update Posted : December 18, 2015
Sponsor:
Information provided by (Responsible Party):

November 3, 2009
November 4, 2009
December 18, 2015
November 2008
June 2011   (Final data collection date for primary outcome measure)
Pain relief [ Time Frame: 3 times in 30 to 60 minutes post-application ]
Same as current
Complete list of historical versions of study NCT01007747 on ClinicalTrials.gov Archive Site
Response to therapy at 30 to 60 minutes, they will be asked to apply the oil to painful area daily [ Time Frame: Daily over 1 week ]
Same as current
Not Provided
Not Provided
 
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
The purpose of this study is to determine if Geranium oil will relieve a variety of neuropathic pain and some pain relief will last more than 48 hours.
EPT 100 study is designed to identify the percentage of people who experience neuropathic pain relief from topical geranium oil from Reunion Island, determine which neuropathic pain conditions respond best and define the time course of the pain relief.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Neuropathic Pain
Other: Geranium oil
Daily topical application over neuropathic pain
Experimental: Geranium oil
Intervention: Other: Geranium oil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
166
October 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age or oler
  • Neuralgia or neuropathy with daily pain
  • At least moderate intensity pain
  • Signed informed consent

Exclusion Criteria:

  • Pregnant or nursing
  • Known allergies to geranium oil or geranium oil fractions
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01007747
PBRC 21033
No
Not Provided
Not Provided
Frank Greenway, Pennington Biomedical Research Center
Pennington Biomedical Research Center
Not Provided
Not Provided
Pennington Biomedical Research Center
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP